1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
KUKJE PHARMA Co., Ltd.

KUKJE PHARMA Co., Ltd.

002720.KS
KUKJE PHARMA Co., Ltd.KR flagKorea Exchange
3,455.00
KRW
+85.00
- -
73.11BMarket Cap
KUKJE PHARMA Co., Ltd.
002720.KS
(Korea Exchange)

Recent

price

3,455.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6,993.86
5,267.89
6,340.35
6,028.89
6,122.47
5,787.59
5,847.79
6,119.12
5,302.96
5,484.16
6,135.62
5,642.65
5,964.52
6,675.99
7,695.13
8,624.41
8,627.56
Revenue per Share
229.75
46.61
-947.3
106.36
-346.67
-292.38
37.46
54.2
107.98
-234.96
103.66
-73.47
167.62
-415
256
280
290.49
Basic EPS, GAAP
-207.81
822.96
-0.98
-319.32
-122.54
-308.12
649.85
-164.92
482.43
-112.67
-305.83
359.85
246.29
124.73
46.49
96.65
-47.02
Free Cash Flow per Basic Share
19.71
19.71
13.93
- -
7.17
7.27
- -
7.83
8.13
25.42
- -
- -
- -
- -
- -
30.02
- -
Dividend per Share
2,962.67
2,698.07
1,714.33
1,885.84
1,507.63
1,167.27
1,162.44
1,223.27
1,227.23
880.17
1,009.76
959.9
1,249.7
876.28
1,306.57
1,563.75
1,613.14
Book Value per Share
4,043.9
3,702.22
2,714.4
2,867.96
2,505.06
3,330.89
3,204.81
3,224.8
3,290.94
2,925.46
3,247.05
3,169.17
3,437.53
4,144
4,361.35
4,733.26
4,709.93
Tangible Book Value per Share
19
20
20
20
20
20
21
20
20
20
21
21
21
20
20
20
21
Basic Weighted Avg Shares
131,308
104,857
126,768
120,461
122,426
117,637
120,684
123,310
107,681
111,122
130,395
119,746
126,583
135,373
156,463
175,496
177,972
Sales/Revenue/Turnover
6.1
2.48
-11.6
0.87
-1.16
1.78
3.29
2.08
3.05
5.01
4.63
-1.4
4.17
-1.47
4.28
3.52
3.29
Operating Margin (%)
4,049
3,096
4,152
4,077
3,780
3,357
2,887
2,642
2,741
3,251
3,626
4,419
4,488
4,204
3,203
3,226
3,279
Depreciation Expense
4,314
928
-18,940
2,125
-6,932
-5,943
773
1,092
2,193
-4,761
2,203
-1,559
3,557
-8,415
5,205
5,698
5,992
Net Income, GAAP
44.73
48.38
- -
- -
- -
- -
54.87
49.4
22.87
4,021.09
60.77
- -
25.34
- -
21.23
11.46
12.29
Effective Tax Rate (%)
3.29
0.88
-14.94
1.76
-5.66
-5.05
0.64
0.89
2.04
-4.28
1.69
-1.3
2.81
-6.22
3.33
3.25
3.37
Profit Margin (%)
36,500
61,140
12,629
39,226
16,354
34,521
10,506
8,960
6,360
1,884
-5,417
-6,319
680
-4,568
28,427
5,358
5,512
Working Capital
10,420
31,998
750
24,250
7,000
27,000
2,000
4,000
- -
2,256
3,792
1,620
1,196
476
27,342
294
727
LT Debt
75,942
74,793
55,352
58,329
50,853
68,459
67,519
67,778
68,698
60,954
70,499
68,588
74,079
84,950
89,548
97,702
98,504
Total Equity
3.87
1.17
- -
- -
- -
- -
1.72
1.3
2.58
-226.18
2.31
- -
3.88
- -
4.5
4.39
4.17
Return on Invested Capital (%)
5.66
1.7
- -
- -
- -
- -
2.12
2.74
5.12
-71.88
4.36
- -
7.75
- -
11.78
10.98
11.1
Return on Capital (%)
8.04
1.7
-43.05
5.91
-20.44
-22.06
3.24
4.49
8.85
-22.27
11.21
-7.45
15.17
-38
23.48
19.52
19.63
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
30,138
30,110
30,193
LT Borrowings
- -
- -
- -
LT Finance Leases
312
294
727
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
21
21
Market Capitalization
88,996
87,571
98,706

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
72,453
67,377
64,721
Cash, Cash Equivalents & STI
18,103
10,724
9,377
Accounts Receivable, Net
23,415
23,978
25,986
Inventories
24,935
25,850
23,728
Total Current Liabilities
61,095
62,020
59,209
Payables & Accruals
- -
- -
- -
ST Debt
30,138
30,110
30,193
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.92%
6.9%
9.11%
Free Cash Flow
-102.75%
-51.04%
108.07%
Net Income, GAAP
-142.23%
-197.58%
9.46%
Sales/Revenue/Turnover
4.49%
6.44%
12.16%
Total Cash Common Dividend
- -
- -
18.59%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37,534
37,643
39,651
41,635
156,463
2025
41,504
45,023
45,633
43,336
175,496
2026
43,980
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
135
29
57
- -
256
2025
91
130.7
94
- -
280
2026
101.53
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
30.02
2026
- -
- -
- -
- -
- -
Similar Companies
Enorama Pharma AB (publ) (ERMA.ST)
COSCIENS Biopharma Inc. (CSCIF)
Jenkem Technology Co., Ltd. (688356.SS)
Trees Corporation (TREE.NE)
White River Energy Corp. (WTRV)
Quest Laboratories Ltd. (QUESTLAB.NS)
Business
Kukje Pharma Co., Ltd. (002720.KS) manufactures, imports, exports, sells and distributes pharmaceutical products in South Korea. The company offers a broad portfolio of prescription and over-the-counter medications, including antibiotics such as cephalosporins, quinolones, tetracyclines, aminoglycosides and macrolides; ophthalmic agents encompassing RebaEye Ophthalmic Solution with rebamipide for dry eye syndrome, Cualone Eye Drops featuring sodium hyaluronate artificial tears in multiple concentrations, and DiquEye Eye Drops with diquafosol sodium; antifungal and antiviral agents; adrenal corticosteroids; central nervous system and osteoporotic agents; antihistamines; non-steroidal anti-inflammatory drugs and other analgesics; gastrointestinal and cardiovascular agents; antidiabetics; genitourinary and respiratory agents; vitamins; nutritional supplements; cosmetics; and health care products, alongside raw materials, intermediates and side chain products. Founded in 1959 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, Kukje Pharma operates primarily in the domestic market with exports to regions including the U.A.E., China, Hong Kong, Malaysia, Qatar and Vietnam, serving hospitals, pharmacies and international distributors through approximately 244 employees. Recent developments include a co-promotion agreement signed with UK Chemipharm to jointly market and distribute five products from the UK Kit lineup, such as Trison Kit, aimed at enhancing clinical product awareness and patient benefits; plans to expand its Anseong Plant by adding a new production line for eye drops to boost manufacturing capacity; and ongoing efforts to grow its contract manufacturing organization business alongside new generic drug launches in antibiotics, respiratory and ophthalmic categories.